EphA10 Inhibitors

Dasatinib is a SRC family kinase inhibitor that can also inhibit EphA10 by targeting its kinase domain. By binding to the ATP-binding site of the kinase domain, Dasatinib can block the phosphorylation activity of EphA10, which is essential for its function in signal transduction.

Erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, can attenuate EphA10 activity. As EGFR signaling can lead to phosphorylation and activation of various Eph receptors, inhibition of EGFR by Erlotinib can indirectly decrease EphA10 phosphorylation and activity.

Lapatinib is a dual tyrosine kinase inhibitor against EGFR and HER2/neu which could also interfere with EphA10 function. By inhibiting upstream signaling pathways involving EGFR and HER2/neu, Lapatinib may reduce the activation of downstream kinases such as EphA10.

Sorafenib is a multi-kinase inhibitor that targets RAF kinases, VEGFR, and PDGFR, among others. By blocking these kinases, Sorafenib can disrupt signaling pathways that may cross-talk with EphA10, leading to a reduction in its activation and signaling capacity.

Sunitinib is a receptor tyrosine kinase inhibitor that targets PDGF receptors, VEGFRs, and other kinases. Through the inhibition of these kinases, Sunitinib can suppress signaling pathways that involve EphA10, ultimately leading to a decrease in EphA10-mediated signaling processes.

Pazopanib is a multi-targeted receptor tyrosine kinase inhibitor that affects VEGFR, PDGFR, and c-kit. By interfering with these kinases, Pazopanib may also inhibit signaling cascades that interact with or activate EphA10.

Vandetanib is an inhibitor of VEGFR, EGFR and RET-tyrosine kinases. By inhibiting these receptors, Vandetanib can disrupt signaling pathways that could indirectly reduce EphA10 activation, since EphA10 is known to engage in cross-talk with these pathways.

Ponatinib is a multi-targeted kinase inhibitor with activity against Bcr-Abl and several other tyrosine kinases. By inhibiting these kinases, Ponatinib can impede signaling pathways that are associated with EphA10 activation and function.

Nilotinib is a selective Bcr-Abl tyrosine kinase inhibitor that can also inhibit various kinases within the Src family. Src family kinases are involved in the regulation of Eph receptors; thus, Nilotinib can indirectly inhibit EphA10 activity by targeting these regulatory kinases.

Lenvatinib is a multi-target inhibitor of VEGFR1-3, FGFR1-4, PDGFR alpha, RET and c-kit. By blocking these kinases, Lenvatinib can inhibit signaling cascades that could lead to the activation of EphA10, though its primary target is not EphA10 itself.